1. Introduction {#sec1}
===============

Multiple myeloma (MM) is a lymphoid cancer that is characterized by monoclonal proliferation of malignant plasma cells in the bone marrow, monoclonal protein in the serum, and organ dysfunction \[[@B1]\]. Chronic myeloid leukemia (CML) is a clonal disorder of myeloid origin that is characterized by the Philadelphia chromosome, t(9; 22) (q34; q11), in which the *BCR-ABL* fusion gene is created. Several types of *BCR-ABL* are known, with the p210 and p190 types being the most common, distinguished by the break point in the *BCR* gene. The vast majority of CML cases result from the p210-type of *BCR-ABL*, while the p190-type is rarely found in CML \[[@B2]\]. The coexistence of MM and CML in the same patient is rare, with only 22 reported cases \[[@B3]--[@B23]\], all involving p210 *BCR-ABL*. Therefore, we report a case of coexisting MM and CML with p190 *BCR-ABL*. Given the rarity of this case, we also discuss the origins of these hematologic malignancies and review the relevant literature.

2. Case Report {#sec2}
==============

A 76-year-old man was referred to our hospital in September 201X, because of right leg pain, lower back pain, and weight loss of 3 kg. Lumbar magnetic resonance imaging and computed tomography (CT) suggested the presence of lumbar spinal canal stenosis and a sacral tumor ([Figure 1(a)](#fig1){ref-type="fig"}). Laboratory testing revealed a markedly elevated serum IgG level (5,436 mg/dL, normal: 800--1,800 mg/dL) and an elevated serum beta-2 microglobulin level (4.1 *µ*g/mL, normal: 0--3 *µ*g/mL), although there were no signs of anemia, renal dysfunction, or proteinuria. Serum immunofixation revealed IgGκ-type M-protein, with an estimated serum-free κ and *λ* chain ratio of 21.5 : 1 ([Figure 1(b)](#fig1){ref-type="fig"}). Microscopic examination and flow cytometric analysis of bone marrow aspirate revealed elevated numbers of CD138-positive abnormal plasma cells. Cytogenetic analysis of the bone marrow revealed 46XY, and the patient was diagnosed as having MM (R-ISS, stage II). Chimeric p190 *BCR-ABL* mRNA was not detected in the bone marrow sample at this point. The patient underwent two cycles of bortezomib plus dexamethasone and two cycles of cyclophosphamide, bortezomib, and dexamethasone (CBD) but did not respond to either treatment regimen. The treatment was switched to lenalidomide (25 mg/day) plus dexamethasone (20 mg/week; Ld therapy), and there was a marked response, with a substantial decrease in the M-protein and disappearance of the sacral tumor on CT. After 24 cycles of Ld therapy, the patient achieved a partial response based on the International Myeloma Working Group criteria.

In December 201X+2, the patient developed leukocytosis (white blood cell count: 35.8 × 10^9^/L) and thrombocytopenia (platelet count: 3 × 10^9^/L). Bone marrow biopsy and aspiration revealed hypercellularity with a marked increase in myeloid lineage cells but without an increase in blast cells (4%). Cytogenetic analysis revealed 46XY t(9; 22) (q34; q11.2) in 20 of 20 cells, and fluorescence in situ hybridization (FISH) analysis revealed that 99.5% of the cells were positive for *BCR-ABL*. Peripheral blood neutrophils were also positive for *BCR-ABL* (98.8%) (Figures [2](#fig2){ref-type="fig"}--[2](#fig2){ref-type="fig"}). Chimeric p190, but not p210, *BCR-ABL* mRNA was detected by using polymerase chain reaction ([Figure 2](#fig2){ref-type="fig"}). The diagnosis was confirmed to be CML with p190 *BCR-ABL* in the accelerated phase (AP), which coexisted with MM (a maintained partial response). Dasatinib treatment (100 mg/day) was started immediately. The dose was subsequently decreased to 50 mg/day, due to the persistence of thrombocytopenia. In April 201X+3, a bone marrow examination indicated that the patient had achieved a second chronic phase, with 31% of this cells being positive for *BCR-ABL* upon FISH analysis, and that his peripheral blood count had normalized. However, 5 months later, FISH analysis revealed that 85.8% of his bone marrow cells were positive for *BCR-ABL*, and subsequently, his treatment was changed from dasatinib to bosutinib. This switch appeared to be ineffective, as no decrease in the *BCR-ABL*-positive bone marrow cells was detected after 2 months.

3. Discussion {#sec3}
=============

There have only been 24 cases of coexisting MM and CML reported ([Table 1](#tab1){ref-type="table"}) \[[@B3]--[@B25]\]. MM and CML were diagnosed simultaneously in 9 cases, and the diagnoses were sequential in the remaining cases, with MM being diagnosed first in 8 cases and CML being diagnosed first in 7 cases. Among the previous reports, all genotypes confirmed by PCR were p210-CML in patients with coexisting MM and CML. Our case is the first reported of MM coexisting with p190-CML in the same patient. The intervals between the sequential diagnoses ranged from 3 months to 120 months. Multiple possibilities could be considered regarding the association between MM and CML. First, these two malignancies could occur independently, and their coexistence, while very rare, could be simply coincidence. Second, common precursors, referred to as "clonal hematopoiesis of indeterminate potential (CHIP)," give rise to both MM and CML cells in a patient. Given our patient\'s relatively advanced age, it is possible that CHIP had a common origin, although we have no direct evidence to support this possibility. A third possible explanation is that the second disease might be a therapy-related malignancy that develops after treatment for the first disease. In the present case, the diagnosis of MM was followed by that of CML. The frequency of secondary carcinogenesis in patients with MM was evaluated for cohorts participating in clinical trials with lenalidomide, which were conducted from 2000 through 2012 \[[@B24]\]. This report showed that the incidence of secondary hematologic malignancies was increased in patients who concurrently received melphalan and lenalidomide, while it did not increase in those receiving other treatment protocols, regardless of whether lenalidomide was included \[[@B26]\]. There is no clear evidence that lenalidomide is carcinogenic, and there has only been one reported case of CML that developed after lenalidomide treatment. Therefore, the increased incidence of hematologic malignancies has been attributed to melphalan, because alkylating agents such as melphalan are known to cause therapy-related myelodysplastic syndromes. According to previous case reports of MM coexisting with CML, many patients received alkylating agents as treatment for MM ([Table 1](#tab1){ref-type="table"}). In the present case, a small dose of an alkylating agent (cyclophosphamide; total: 2,400 mg/m^2^) was administered during two cycles of CBD therapy. We, therefore, needed to consider the possibility that the cyclophosphamide treatment caused the CML. However, an accumulation of case reports and further investigations are required to draw definitive conclusions.

Although p190 *BCR-ABL* CML has been reported in 1% of CML cases, there have been several clinical observations suggesting that CML with p190 *BCR-ABL* is difficult to treat \[[@B27]\]. Furthermore, p190 *BCR-ABL* has been identified as a marker for high-risk disease, and early stem cell transplantation has been recommended if the patient is eligible \[[@B26]\]. Our patient received initial treatment of dasatinib for his CML in AP with p190 *BCR-ABL*, which provided a partial cytogenetic response at 4 months after the diagnosis. Although the long-term effects of dasatinib treatment in patients with p190 *BCR-ABL* CML are unknown, in the present case, the duration of response to dasatinib was relatively short.
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![(a) Computed tomography (CT) at the time of multiple myeloma (MM) diagnosis. Sacral tumor and lytic bone involvement in the lumbar spine are shown (arrow). (b) Serum immunofixation at the time of MM diagnosis. SP, size marker; G IgG; A IgA; M IgM; κ, kappa chain; *λ,* lambda chain.](CRIHEM2018-7863943.001){#fig1}

![(a) Karyotype from a bone marrow specimen at the time of chronic myeloid leukemia (CML) diagnosis. t(9; 22) is shown by using arrows. (b) Fluorescence in situ hybridization for peripheral blood cells. Arrowheads, *BCR-ABL* fusion gene (yellow); large arrows, *ABL* signal (red); small arrows, *BCR* signal (green). (c) Polymerase chain reaction (PCR) amplification analysis from the bone marrow specimen taken at the time of CML diagnosis. Lane 1, size marker; lane 2, p210 negative control; lane 3, p190 negative control; lane 4, p210 positive control; lane 5, p190 positive control; lane 6, p210 patient\'s sample; lane 7, p190 patient\'s sample.](CRIHEM2018-7863943.002){#fig2}

###### 

Concomitant multiple myeloma and chronic myeloid leukemia cases.

  Pt   Age/Sex   Year   First disease   Diagnosis interval (month)   Type of M-protein   Therapy for MM       Therapy for CML         Confirmation method of Ph+   Type of Ph   Reference
  ---- --------- ------ --------------- ---------------------------- ------------------- -------------------- ----------------------- ---------------------------- ------------ ---------------------------------------
  1    77M       1972   MM              33                           BJP                 No treatment         No treatment            Chr                                       MacSween and Langley \[[@B3]\]
  2    65/F      1974   CML             113                          IgG-κ               No treatment         Busulfan                Chr                                       Derghazarian and Whittemore \[[@B4]\]
  3    58/M      1982   MM and CML      Simultaneous                 IgG-κ               MP, RT               HU, Busulfan,           Chr                                       Boots and Pegrum \[[@B5]\]
  4    71/M      1993   MM              24                           IgG-κ               MP, RT               HU                      Chr                                       Klenn et al. \[[@B6]\]
  5    72/F      1998   MM and CML      Simultaneous                 IgG-κ               VP                   IFN-*α*                 Chr, PCR, FISH               P210         Tanaka et al. \[[@B7]\]
  6    70/M      1999   MM              33                           IgG-κ               Not reported         Not reported            Chr                                       Nitta et al. \[[@B8]\]
  7    81/M      2001   MM and CML      Simultaneous                 IgA-κ               MP                   No treatment            Chr, PCR                                  Alvarez-Larrán et al. \[[@B9]\]
  8    66/M      2003   MM and CML      Simultaneous                 IgG-κ               MP                   INF-*α*, HU, Busulfan   Chr, PCR, FISH               P210         Schwarzmeier et al. \[[@B10]\]
  9    47/M      2003   MM              33                           BJP                 LOAD-IN              Not reported            Chr                                       Nakagawa \[[@B11]\]
  10   68/M      2005   CML             20                           IgG-*λ*             MP                   IFN-*α*, imatinib       Chr, PCR                     P210         Garipidou et al. \[[@B12]\]
  11   85/F      2005   MM and CML      Simultaneous                 IgG-*λ*             Not reported         Not reported            Chr, PCR                     P210         Wakayama et al. \[[@B13]\]
  12   76/M      2009   CML             14                           IgA-κ               MP                   IFN-*α*, imatinib       Chr, PCR, FISH               P210         Galanopoulos et al. \[[@B14]\]
  13   57/F      2009   CML             65                           IgA-κ               TD, VAD              Imatinib                Chr, PCR                     P210         Michael et al. \[[@B15]\]
  14   72/F      2010   CML             3                            IgG-κ               No treatment         Imatinib                Chr, PCR                     P210         Ide et al. \[[@B16]\]
  15   71/F      2012   MM and CML      Simultaneous                 IgG-κ               MP, Bd, Ld           Imatinib                Chr                                       Offiah et al. \[[@B17]\]
  16   64/F      2013   MM and CML      Simultaneous                 IgA-κ               BD                   Imatinib                Chr                                       Romanenko et al. \[[@B18]\]
  17   62/F      2013   MM              17                           IgG-κ               RT, VCD, VCDD, VRD   Dasatinib               Chr, PCR                     P210         Ragupathi et al. \[[@B19]\]
  18   77/M      2014   MM and CML      Simultaneous                 IgG-κ               RT, BD               No treatment            Chr, PCR                     P210         Maerki et al. \[[@B20]\]
  19   60/M      2014   MM              48                           IgG-κ               RT, Ld               HU, dasatinib           Chr, FISH                                 Alsidawi et al. \[[@B21]\]
  20   63/F      2012   CML             120                          IgG-κ               BD, Ld               Imatinib                Chr, PCR                     P210         Pessach et al. \[[@B22]\]
  21   68/M      2012   MM              54                           IgG-*λ*             VAD                  Imatinib                Chr, PCR                     P210         Pessach et al. \[[@B22]\]
  22   76/M      2015   CML             38                           IgA-*λ*             No treatment         Imatinib                Chr, PCR                                  Ahn et al. \[[@B23]\]
  23   51/F      2016   MM              Unknown                      IgG                 BD                   Imatinib                Chr, PCR                                  Wolleschak and Heidel \[[@B24]\]
  24   88/M      2016   MM and CML      Simultaneous                 IgD-κ               VRD                  Imatinib                Chr                                       Ali et al. \[[@B25]\]
  25   76/M      2018   MM              28                           IgG-κ               Ld                   Dasatinib, bosutinib    Chr, PCR, FISH               P190         Our case

BJP, Bence Jones protein; MP, melphalan, prednisolone; RT, radiation therapy; HU, hydroxyurea; LOAD-IN, melphalan, ranimustine, vincristine, IFN-*α*; PSL, prednisolone; VCD, bortezomib, cyclophosphamide, dexamethasone; VCDD, VCD plus doxorubicin; VRD, bortezomib, lenalidomide, dexamethasone; Ld, lenalidomide, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; BD, bortezomib, dexamethasone; CBD, BD plus cyclophosphamide; Rd, lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; Chr, chromosome; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization.
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